Notice of the Cambridge biotech's layoffs came less than two weeks after Sage announced it would be acquired by ...

After Biogen failed with a takeover bid in January, Supernus has swooped in to acquire the postpartum depression pill developer.

Following negative results, the company doesn’t plan to further test SAGE-718 in Parkinson’s. Other studies in Huntington’s and Alzheimer’s remain ongoing.

In what one analyst described as an “unremarkable” outcome, the brain drug developer is being acquired for just $8.50 per share, plus non-guaranteed additional payouts, after a series of stumbles that ...

Drugmakers Sage Therapeutics and Biogen are still ironing out how much their newly approved postpartum depression medication, zuranolone, will cost once it’s made commercially available in the ...

Sage has one other approved postpartum depression drug, Zulresso, which works the same way zuranolone does but has to be administered during a 60-hour inpatient IV.

Two weeks after Supernus Pharmaceuticals unveiled the proposed acquisition of Sage Therapeutics, all 338 employees from the latter company are being canned, ...

The FDA had asked Biogen and Sage Therapeutics to provide more clinical data supporting Zurzuvae in major depressive disorder. Citing the time and expense of additional clinical trials, the ...

The experts agreed that carnosic acid could potentially improve the inflammation that generally occurs in most aging brains. There are cautions however.

Sage Therapeutics Inc. plunged after a mid-stage study of its drug to treat essential tremor failed, the second setback for its pipeline in three months.

The Food and Drug Administration on Friday granted approval to a new kind of antidepressant, clearing an oral medicine developed by partners Sage Therapeutics and Biogen for postpartum depression ...

Biogen's $3bn alliance with Sage has had another setback after a drug for essential tremor failed a phase 2 study.